BLFS: Q2 Results. Guidance Affirmed
Brian Marckx, CFA
BioLife Solutions (
reported financial results for the second quarter ending June 30,
2012 on August 14th. Revenue came in at $1.1 million, as
expected following the company's pre-announcement in early
July. Revenue was an all-time quarterly record and
represented growth of 76% yoy and 31% sequentially. This is
also the eighth consecutive quarter of sequential revenue
growth. BioLife also notes that they have now completed the
expansion of their corporate office and operations space as well as
the build-out of their second clean room.
Also as expected, contract manufacturing revenue was a significant
contributor following commencement of deliveries to the new
contract manufacturing customer during Q2. Contract
manufacturing revenue was $341k in Q2, up from just $67k in Q2 2011
and $0 in the first quarter of this year. For Q2 2012
contract manufacturing accounted for 31% of total revenue and
contributed 58% and 131% of the total revenue growth on a yoy and
sequential basis, respectively.
Product sales to both direct ($497k) and indirect ($254k) customers
were also very strong on a yoy basis, up 22% and 79%
respectively. While direct customer sales fell 33%
sequentially, we would not read much into that as the company's
product sales can be choppy quarter-to-quarter - we also note that
indirect sales increased 79% sequentially. Importantly and
likely more representative of a long-term outlook for product
sales, BioLife recently added headcount to its direct and indirect
sales teams (as well as production personnel) in order "to manage
growing demand and projections." In the earnings release BLFS
affirms previously issued revenue guidance of $4.1 million for
Gross margin was 41.5%, slightly more narrow than our 43.3%
estimate. As expected GM came in significantly from Q1
(58.6%) as a result of the lower margin from contract manufacturing
sales and increased costs related ramp up in production to meet
demand from the new customer. We model a consistent widening
of GM throughout the remainder of 2012.
Operating expenses came in about 15% higher ($762A vs $665E) than
our estimate, most of which relates to the addition to the sales
staff during the quarter.
Net income and EPS were ($499k) and (0.01) compared to our ($394k)
and ($0.01) estimates.
BioLife exited Q2 with $155k in cash and equivalents, up from $71k
at the end of Q1. Cash used in operating activities in Q2 was
an inflow of $761k, benefitting from $785k in deferred rent related
to the tenant improvements to the additional manufacturing
space - these tenant improvements were funded by the landlord
but will be amortized back to rent beginning in January 2013.
Cash balance also benefitted from $300k in sales of promissory
notes during Q2. Stripping out changes in working capital
(proxy for EBITDA), cash used in operating activities was an
outflow of $400k in Q2. BLFS continues to expect to achieve
positive cash flow from operations by the end of 2012.
Out Outlook remains intact following Q2 results as does our
recommendation. We continue to model 2012 revenue of $3.8
million and EPS of ($0.03). We are maintaining our Outperform
rating and moving our price target from $0.25/share to $0.30/share
based on an increase in comp valuations (see our valuation in our
full report on BLFS).
to access a free copy of the full BLFS research report.
BIOLIFE SOL INC (BLFS): Free Stock Analysis
To read this article on Zacks.com click here.